These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35251795)

  • 1. Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India.
    Verma M; Sharma S; Kumar A; Hakim A; Bhansali S; Meena R
    Cureus; 2022 Jan; 14(1):e21721. PubMed ID: 35251795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Vaccination on COVID-19 Severity and Outcome: A Comparative Study in a Tertiary Care Hospital.
    Yadav YR; Maheshwari S; Garg A; Ram A; Singh S; Mangal S; Maheshwari K; Notani V; Sharma S; Bansal V
    J Assoc Physicians India; 2023 Dec; 71(12):14-16. PubMed ID: 38736048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India.
    Doke PP; Mhaske ST; Oka G; Kulkarni R; Muley V; Mishra AC; Arankalle VA
    Front Public Health; 2022; 10():1040012. PubMed ID: 36711329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.
    Mohanasundaram K; Santhanam S; Natarajan R; Murugesan H; Nambi T; Chilikuri B; Nallasivan S
    Int J Rheum Dis; 2022 Sep; 25(9):1046-1052. PubMed ID: 35773944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 patients' clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India.
    Patel AK; Patel D; Shevkani M; Shah A; Madan S; Gohel S; Chhatwani C; Doshi A; Patel V; Sukhwani K; Kareliya H; Shah V; Savaj P; Rana M; Patel KK; Bakshi H
    Indian J Med Microbiol; 2023; 41():28-32. PubMed ID: 36870745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
    Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
    Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
    Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India.
    Bhattacharya A; Ranjan P; Ghosh T; Agarwal H; Seth S; Maher GT; Upadhyay AD; Kumar A; Baitha U; Gupta G; Prakash B; Dwivedi SN; Wig N
    Diabetes Metab Syndr; 2021; 15(5):102238. PubMed ID: 34364299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severity and Outcome of Post-Vaccine COVID-19 among Healthcare Workers in a University Hospital in India.
    Vishnoi J; Sharma RK; Patel J; Sharma JC; Sharma KR; Mehta U
    J Med Life; 2023 May; 16(5):782-793. PubMed ID: 37520491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prior vaccination with Covishield
    Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
    Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, severity, and risk factor of breakthrough infection after vaccination with either the Covaxin or the Covishield among healthcare workers: A nationwide cross-sectional study.
    Krishna B; Gupta A; Meena K; Gaba A; Krishna S; Jyoti R; Aeron N; Prashanth S; Samriti ; Ganapathy U
    J Anaesthesiol Clin Pharmacol; 2022 Jul; 38(Suppl 1):S66-S78. PubMed ID: 36060166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study.
    Hippisley-Cox J; Coupland CA; Mehta N; Keogh RH; Diaz-Ordaz K; Khunti K; Lyons RA; Kee F; Sheikh A; Rahman S; Valabhji J; Harrison EM; Sellen P; Haq N; Semple MG; Johnson PWM; Hayward A; Nguyen-Van-Tam JS
    BMJ; 2021 Sep; 374():n2244. PubMed ID: 34535466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Smits PD; Gratzl S; Simonov M; Nachimuthu SK; Goodwin Cartwright BM; Wang MD; Baker C; Rodriguez P; Bogiages M; Althouse BM; Stucky NL
    Vaccine; 2023 Apr; 41(15):2447-2455. PubMed ID: 36803895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
    Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
    J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
    Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
    JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital.
    S M; Hr C
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
    Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.